Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Open Label, Early Stopping Design, Proof Of Concept Study With Tasquinimod In Treating Patients With Advanced Or Metastatic Hepatocellular, Ovarian, Renal Cell And Gastric Carcinomas

NCT01743469 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT01743469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01743469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Open Label, Early Stopping Design, Proof Of Concept Study With Tasquinimod In Treating Patients With Advanced Or Metastatic Hepatocellular, Ovarian, Renal Cell And Gastric Carcinomas
Lead sponsor
Ipsen
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2012
Completion date
April 30, 2016
Enrollment
201 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic gastric carcinoma, advanced or metastatic hepatocellular cancer, advanced or metastatic ovarian cancer, metastatic renal cell cancer